I think it's pretty fair value where it is ~$100M at this stage really should be pretty happy with 10% cash - still very discovery/pre-clinical and a long way from the clinic. Yes it's very exciting chasing holy grails but again still very early - I think it really needs a deal to price value to go higher at present it's just Genentech which looks well and truly priced in. I know I know $150m potential but so tail ended and a long way from the tail. Even once they get to clinic everything still faces those daunting stats 10% of successful Phase 1 candidates (cancer drugs way tighter with only 5%) then moves up to ~30% at Phase II etc etc gain eventual approval.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)